AnalystBook Research · Company Intelligence

Lantheus Holdings, Inc.

LNTHNasdaq

Built from Lantheus Holdings, Inc.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

Revenue increased 0.5% to $1.54B, while Net income decreased 25.2% to $233.6M.

The read at a glance✓ Audited against SEC data
  • ScaleFY2025 revenue $1.54BOK
  • ProfitabilityNet income $233.6MOK
  • Cash generationFree cash flow $390.1MOK
  • AccountingFormula-grey distress score · no manipulation flag · earnings quality safeNote
  • Insiders0 buys; 5 sells in 365 daysNote
  • Capitalshare repurchases were $300.0MNote

Business

Lantheus Holdings, Inc.: Our ability to continue to (A) grow the appropriate use of DEFINITY in suboptimal echocardiograms in a competitive environment, (B) mitigate the risk of generic competition as a result of patent and regulatory exclusivity expirations, (C) maintain DEFINITY as the most utilized ultrasound enhancing agent, and (D) have third parties manufacture our products and our ability to manufacture DEFINITY in our in-house manufacturing facility.

Where the revenue comes from

Fiscal 2025, as Lantheus Holdings, Inc. reports it. History and quarterly detail are in the app.

  • Product$1.5B
  • Radiopharmaceutical Oncology$989.1M
  • PYLARIFY$989.1M
  • Total Precision Diagnostics$493.1M
  • Definity$330.2M

Leadership changes

From Lantheus Holdings, Inc.'s own filings, the day they're filed.

  • Andrea Sabens · Chief Accounting Officer · departureeff. 2024-07-01
  • Kimberly Brown · Chief Accounting Officer · appointmenteff. 2024-07-01
  • Julie McHugh · Director · appointmenteff. 2024-01-23

Latest filings

  • 10-Q · Quarterly report2026-08-06
  • 8-K · Company announcement2026-08-06
  • 8-K · Company announcement2026-08-04
  • 8-K · Company announcement2026-08-03
  • 8-K · Company announcement2026-05-07
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about Lantheus Holdings, Inc., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.